Fort Myers, FL, November 14, 2010 --(PR.com
)-- National Research on Calypso® system’s effectiveness in guiding radiation treatment.
Dr. Constantine Mantz, a radiation oncologist and director of research for 21st Century Oncology, presented his clinical research findings using the Calypso® 4D localization system in conjunction with stereotactic body radiation therapy for the treatment of prostate cancer at the American Society of Radiation Oncology’s (ASTRO) 52nd Annual Meeting held last week in San Diego. His abstract was one of 100 selected of the more than 3,000 submissions the conference received this year. The findings are based on his research conducted in Southwest Florida. Mantz is also the Medical Director of the Prostate Cancer Institute.
This research follows a similar study he published in the medical journal Urology earlier this year, in which Mantz reported that the precision with which physicians can target radiation beams using the Calypso system enables them to treat prostate cancer with significantly less risk of unwanted side effects. In this related study, radiation’s impact on urinary, bowel and sexual function was greatly reduced over conventional therapy.
“It was an honor to present this research to my peers. I’m particularly proud of the fact that we were able to conduct this nationally recognized work here in Southwest Florida and establish 21st Century Oncology as a leader in prostate cancer radiotherapy,” Mantz says.
The Calypso system tracks the movement of the prostate in real-time during a treatment session and allows for pinpoint accuracy in radiation delivery. Prior to radiotherapy, tiny electromagnetic devices called beacon transponders are implanted in the patient’s prostate. These transponders allow physicians to monitor the natural movement of the prostate during treatment and ensure that the prostate stays within the radiation beam. Without Calypso, physicians may set radiation beams to cover a wider area, including healthy tissue, to account for these small movements. The ability to continuously see where the prostate is located in relation to the radiation beam means clinicians can keep the beam’s scope narrow and direct higher, more effective radiation dose to the tumor.
About The Prostate Cancer Institute
The Prostate Cancer Institute (PCI) combines the talents of Southwest Florida’s most experienced board-certified urologists and radiation oncologists, giving patients a single point of contact for their prostate cancer treatment needs. Armed with the latest research, cutting edge technology and the most current treatment modalities, our doctors and staff members work together to evaluate and review each individual patients’ treatment options, and collaborates with patients and their families to select the best course to meet their needs. PCI physicians’ expertise has been recognized by professional societies and organizations and, most importantly, patients. For more information, physician referral service or to schedule an appointment, call 800-NEW-HELP or visit www.MensCancerCenter.com.
For further information, contact: Carolyn Rogers
Office 239-278-3900, Cell 239-850-5020